Peptide stacks & synergies

The combination people most ask about: a GLP-1 agonist for fat loss paired with a GHRH/GHS-R combination to support lean-mass preservation during the rapid weight loss phase. Mechanistically coherent; combination-specific RCT evidence is the gap.

The "Reddit famous" body-recomposition stack. Triple-receptor incretin agonism for fat loss, mitochondrial-derived peptide for metabolic flexibility, GHRH analog for visceral-fat-specific reduction and GH support. Mechanistically interesting; deeply theoretical.

The most aggressive incretin combination discussed in Reddit's r/Peptides and biohacker communities — combining the deepest weight-loss agent in development with the deepest currently-approved agent. Mechanistically the two compounds heavily overlap, which is the key honest critique. Included here because it is widely discussed; framing requires careful attention to receptor pharmacology. Spoiler: it's not actually a good stack — read on for the honest answer.

The pharmacologic logic behind CagriSema and the broader incretin-plus-amylin direction in modern obesity medicine: pair the GLP-1 (or GLP-1/GIP) appetite-suppression mechanism with amylin's complementary satiety and gastric-emptying biology.

A targeted combination for users where visceral adiposity (rather than overall weight) is the primary clinical concern. Pairs the deepest FDA-approved fat-loss agent with the only peptide specifically validated and approved for visceral fat reduction.

A pharmacologic combination for the rare obesity populations where genetic dysfunction in the leptin-melanocortin pathway is the underlying driver. Setmelanotide directly addresses the affected pathway; GLP-1 adds general weight-management biology on top.

Combining tesofensine's central appetite suppression via triple monoamine reuptake inhibition with semaglutide's or tirzepatide's peripheral incretin signaling. Mechanistically orthogonal — the targets don't overlap. Community-explored for plateau-breaking, non-responder rescue, or maximum-mechanism coverage. No controlled-trial evidence for the combination itself.

CagriSema (cagrilintide + semaglutide) covers peripheral GLP-1 satiety plus amylin signaling. Adding tesofensine layers in central monoamine appetite suppression. Three orthogonal mechanisms simultaneously — incretin, amylin, and central monoamine. Theoretically maximum-coverage weight loss; practically the largest side-effect surface in the weight-loss stack space.

The most-asked and least-answered incretin combination question of 2026. Tirzepatide (GIP/GLP-1 dual) excels at appetite suppression and tolerability; retatrutide (GIP/GLP-1/glucagon triple) adds metabolic rate and fat oxidation via the glucagon arm but reduces appetite less aggressively at comparable doses. Combining them is mechanistically partial-overlap (GIP/GLP-1 redundant; glucagon additive only). A decision-framework analysis of what published evidence supports and what it doesn't.

The most-discussed peptide combination on the internet. BPC-157's broad tissue-protective profile paired with TB-4-derived actin-binding repair signal — strong preclinical record across both compounds, limited combination-specific human evidence.

An expanded four-compound recovery stack combining tissue protection (BPC-157), cell migration (TB-500), immune modulation (thymosin alpha-1), and copper-binding tissue regeneration (GHK-Cu). Trade-off: more arms, less individual-evidence depth, more interaction surface.

A four-compound combination targeting different layers of intestinal barrier biology — mucosal protection, anti-inflammatory signaling, tight-junction modulation, and luminal antimicrobial defense. The most-discussed gut-focused stack in the modern peptide community.

A peptide-based immune-modulation combination drawing on T-cell-rebuilding biology, mucosal antimicrobial defense, and innate immune signaling — with one entry having the strongest approval-grade evidence and others remaining exploratory.

A connective-tissue-specific recovery combination for tendon, ligament, and cartilage injuries. Distinct from the broader Comprehensive Recovery stack by adding direct IGF-1 anabolic signaling and oral collagen substrate to the BPC/TB foundation.

A neurological-recovery-focused combination for post-concussion, mild TBI, and post-stroke rehabilitation contexts. Anchored by Cerebrolysin's controlled-trial evidence in stroke and TBI populations where the molecule is approved abroad.

A widely-marketed four-compound research-peptide blend that has become one of the most-discussed recovery stacks in the modern peptide community. The KLOW acronym is derived from the component initials (K from KPV, L from a community-naming convention, OW from GHK-Cu and similar). All four compounds engage tissue repair, inflammation, and recovery biology through complementary pathways — making this one of the more mechanistically coherent multi-compound recovery stacks despite the absence of combination-specific trial evidence.

The most-discussed growth-hormone-axis combination. CJC-1295 (typically the no-DAC "Mod GRF 1-29" variant) provides GHRH-receptor priming; ipamorelin provides selective ghrelin-receptor stimulation. Together they are designed to mimic a physiologic GH pulse.

The most-discussed direct-anabolic peptide combination in the bodybuilding research community — distinct from GH-secretagogue stacks like CJC/Ipamorelin in that it pairs direct IGF-1 supply with myostatin-pathway suppression. Heavy WADA-banned and grey-market regulatory considerations.

A medical-aging-focused anabolic combination for older adults experiencing sarcopenia (age-related muscle loss) and the visceral-adipose accumulation that often accompanies it. Distinct from the bodybuilding-focused Hypertrophy stack by audience and dose intensity.

A two-compound stack pairing Gonadorelin (synthetic GnRH at the pituitary level) with Kisspeptin (upstream hypothalamic activation) for comprehensive HPG-axis support — most-discussed in TRT-adjuvant contexts where testicular function and fertility preservation matter, and in post-cycle therapy or natural-testosterone recovery contexts. The two-point activation framework is the rationale: Kisspeptin restores the upstream hypothalamic signal pattern, Gonadorelin provides direct pituitary-level stimulation. The combination is theoretically more physiologically complete than either alone.

Three of the most-discussed longevity peptides combined. Mitochondrial-derived peptide for metabolic flexibility, telomerase-related research peptide for cellular aging, cardiolipin-binding peptide for mitochondrial structure protection. Maximum scope for theoretical framing.

A theoretical longevity combination targeting cellular senescence, NAD+ metabolism, glycation/oxidative stress, and direct redox buffering. Each compound represents a distinct longevity-biology axis with substantially different evidence levels.

A four-compound rotational protocol drawn from the Khavinson short-peptide framework — pineal, cortical, vascular, and brain-targeted bioregulators cycled together. Lineage-concentrated evidence base, real research tradition, limited Western validation.

The skin-aging-focused peptide combination drawing on the most-evidence-graded peptide cosmetic ingredient (GHK-Cu), the broader Matrixyl-class signaling peptides, and oral collagen-derived peptides for systemic skin support.

A musculoskeletal-aging-focused combination targeting cartilage, bone, and connective-tissue biology. Pairs the FDA-approved osteoporosis anabolic agent Teriparatide with the Khavinson cartilage and parathyroid bioregulators and copper-peptide ECM support.

A longevity-framed combination using the strong cardiovascular and renal outcomes evidence of GLP-1 therapy as the foundation, with anti-glycation, NAD+-preservation, and antioxidant peptides layered on top. Distinct from weight-loss-focused GLP-1 use.

Two of the most-discussed longevity interventions paired across substantially different aging-biology axes. NAD+ precursors (NR or NMN) target the sirtuin / metabolic / mitochondrial axis; Epitalon targets the telomere / pineal / circadian axis from the Khavinson tradition. Mechanistically orthogonal, anecdotally popular, controlled-evidence-thin for the combination.

The most-discussed peptide combination in the skin, hair, and wound-healing community, anchored by GHK-Cu. The injectable / systemic counterpart to the topical-cosmetic peptide approach — paired with BPC-157 for tissue-healing support and oral collagen peptides for systemic skin substrate. Per-compound evidence is reasonable; combination-specific human data is essentially absent.

A mechanistically clean three-compound mitochondrial stack — each peptide hits a distinct aspect of mitochondrial biology that the others don't cover. Humanin provides cytoprotection and anti-apoptotic signaling. MOTS-c provides AMPK-mediated metabolic signaling and stress-response biology. SS-31 (Elamipretide) provides direct structural protection of inner-mitochondrial-membrane integrity through cardiolipin binding. The three mechanisms are genuinely non-overlapping, making this one of the few peptide stacks where the synergy argument is mechanistically clean rather than redundant. Combination-specific human evidence is essentially absent; per-compound evidence is uneven (SS-31 has the most clinical-trial data; MOTS-c has substantial observational human and preclinical work; Humanin has the thinnest translation pipeline).

A three-compound blend increasingly sold as a packaged research-peptide product, pairing GHK-Cu's collagen and ECM signaling with KPV's NF-κB-mediated anti-inflammatory protection of that very collagen, plus MOTS-c's mitochondrial and metabolic anti-aging arm. The GHK-Cu + KPV pairing is genuinely mechanistically synergistic; MOTS-c is the broader-longevity arm with a looser direct connection. Comprehensive coverage across three anti-aging axes — not tight pharmacologic interlocking.

The most-discussed nootropic peptide combination. Semax provides the cognitive / focus arm (ACTH-fragment-derived); Selank provides the anxiolytic / calming arm (tuftsin-derived). Both originate from the same Russian neuropeptide research lineage.

DSIP for sleep-architecture support paired with Selank for the anxiolytic / sleep-onset arm. Both are research-grade compounds with limited human RCT evidence; the combination addresses two different sleep-disturbance patterns.

A neuroprotection-focused combination drawing on porcine brain extracts (approved abroad), Khavinson short peptides, and an angiotensin IV-derived synaptogenesis peptide. Distinct from the intranasal Semax/Selank stack — this targets cortical and hippocampal biology directly.

PT-141 (FDA-approved bremelanotide) addresses the central desire-and-arousal pathway via melanocortin agonism. Pairing with oxytocin adds a connection / emotional-arousal component. Cleanest evidence in the desire-disorder arm; combination-specific data is more theoretical.

A female-specific sexual wellness combination addressing desire (the FDA-approved indication for PT-141), bonding/connection (oxytocin), and the anxiety-driven dimension of sexual difficulties (selank). Distinct from the general Sexual Wellness Stack by its female-context framing.

A male-context sexual wellness combination addressing desire and arousal (PT-141), nighttime GH-pulse-driven sleep architecture (Modified GRF 1-29), circadian and cognitive support (Pinealon), and the visceral-fat dimension of metabolic-syndrome-related sexual function (Tesamorelin).

A deliberate single-compound counterpoint to the multi-peptide stacks elsewhere on this page. For cardiometabolic risk reduction in obesity with established CV disease, semaglutide alone — supported by SELECT and FLOW — is the most evidence-supported strategy. Adding compounds does not always increase signal.

A vascular-targeted combination drawing on Khavinson's vascular bioregulator program (the older cytomedin Ventfort and the synthetic short-peptide Vesugen) plus cibinetide's documented effects on endothelial and tissue-protective signaling. Distinct mechanisms, modest evidence overall.

A liver-specific metabolic combination for users with NAFLD/NASH-spectrum findings. Pairs the deepest approved fat-loss agent with the only peptide specifically validated for hepatic-fat reduction in metabolic context, plus anti-glycation support for the AGE-driven dimension of metabolic liver disease.

A mechanistically clean pairing: a GLP-1 receptor agonist (semaglutide, tirzepatide) reduces appetite and intake; a liver-selective thyromimetic (resmetirom) accelerates hepatic lipid metabolism and treats MASH directly. The combination addresses the obesity + MASH comorbidity that millions of patients carry — the rationale is mechanistically clean but combination-specific human trial evidence is essentially absent through 2026.